Compare USLM & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USLM | CELC |
|---|---|---|
| Founded | 1948 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 1994 | 2017 |
| Metric | USLM | CELC |
|---|---|---|
| Price | $117.20 | $103.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $106.63 |
| AVG Volume (30 Days) | 80.4K | ★ 537.3K |
| Earning Date | 04-29-2026 | 03-25-2026 |
| Dividend Yield | ★ 0.20% | N/A |
| EPS Growth | ★ 23.22 | N/A |
| EPS | ★ 4.67 | N/A |
| Revenue | ★ $144,435,000.00 | N/A |
| Revenue This Year | $13.29 | N/A |
| Revenue Next Year | $8.70 | N/A |
| P/E Ratio | $25.31 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $80.47 | $7.58 |
| 52 Week High | $137.96 | $120.32 |
| Indicator | USLM | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 47.82 | 40.10 |
| Support Level | $109.01 | $103.65 |
| Resistance Level | $129.25 | $117.27 |
| Average True Range (ATR) | 5.45 | 5.60 |
| MACD | 0.01 | -0.71 |
| Stochastic Oscillator | 21.09 | 6.20 |
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. It supplies its products predominantly to the construction (including highway, road, and building contractors), industrial (including paper and glass manufacturers), environmental (including municipal sanitation and water treatment facilities and flue gas treatment processes), metals (including steel producers), oil and gas services, roof shingle manufacturers and agriculture (including poultry and cattle feed producers) industries. The company operates through its Lime and Limestone Operations segment.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.